Management of Elevated Alkaline Phosphatase During Anti-TB Treatment

Initial Assessment and Monitoring Strategy

The American Thoracic Society recommends continuing anti-TB treatment without interruption and monitoring liver function tests weekly, as isolated ALP elevation without transaminase elevation ≥5× upper limit of normal or bilirubin rise does not meet criteria for stopping hepatotoxic drugs 1, 2, 3
The Infectious Diseases Society of America suggests that critical thresholds for stopping rifampicin, isoniazid, and pyrazinamide are: AST/ALT ≥5× upper limit of normal in asymptomatic patients, AST/ALT ≥3× upper limit of normal WITH hepatitis symptoms, and ANY elevation in bilirubin above normal range 1, 2, 3
The European Respiratory Society recommends excluding alternative causes of ALP elevation, such as biliary tract disease, bone pathology, other hepatotoxic medications, viral hepatitis, and alcohol consumption, before attributing ALP elevation solely to anti-TB drugs 1, 2, 3

The Centers for Disease Control and Prevention advises stopping rifampicin, isoniazid, and pyrazinamide immediately if AST/ALT ≥5× upper limit of normal, AST/ALT ≥3× upper limit of normal WITH symptoms, or ANY rise in bilirubin above normal 4, 5, 1, 2, 3
The World Health Organization recommends continuing ethambutol and adding streptomycin (if renal function permits) for patients with active/infectious TB requiring continued treatment 2, 3

The American College of Chest Physicians suggests that patients at increased risk for hepatotoxicity, including elderly patients, female gender, chronic kidney disease, diabetes mellitus, poor nutritional status, and chronic viral hepatitis B or C carriers, require enhanced monitoring 2
The European Society of Clinical Microbiology and Infectious Diseases advises against stopping treatment prematurely in asymptomatic patients with transaminases <5× upper limit of normal and normal bilirubin, as this risks treatment failure and drug resistance 2, 4, 5, 6